Roche and Genentech to use SurModics tech for Lucentis delivery
This article was originally published in Clinica
Roche and its subsidiary Genentech have bought an excusive licence for SurModics’ drug delivery system, which uses biodegradable microparticles. The firms will use the technology to develop and commercialise a sustained drug delivery formulation of Lucentis, a monoclonal antibody fragment used to treat age-related macular degeneration (AMD). Under the terms of the agreement, SurModics will receive an up-front payment of $3.5m. However, the Eden Prairie, Minnesota-based firm could receive up to $200m in fees and milestone payments, contingent on the successful development and commercialisation of multiple products.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals